NO20072668L - Ny kombinasjon - Google Patents

Ny kombinasjon

Info

Publication number
NO20072668L
NO20072668L NO20072668A NO20072668A NO20072668L NO 20072668 L NO20072668 L NO 20072668L NO 20072668 A NO20072668 A NO 20072668A NO 20072668 A NO20072668 A NO 20072668A NO 20072668 L NO20072668 L NO 20072668L
Authority
NO
Norway
Prior art keywords
new combination
vaccine directed
neu molecule
quinazolinamines
quinazolinamine
Prior art date
Application number
NO20072668A
Other languages
English (en)
Inventor
Catherine Marie Ghislai Gerard
Claudine Elvire Marie Bruck
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of NO20072668L publication Critical patent/NO20072668L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

En metode for behandling av kreft er beskrevet som omfatter administrering av et 4-kinazolinamin og en vaksine rettet mot HER-2/neu molekylet, så vel som en farmasøytisk kombinasjon omfattende 4-kinazolinaminer og en vaksine rettet mot HER-2/neu molekylet.
NO20072668A 2004-12-10 2007-05-25 Ny kombinasjon NO20072668L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0427131.8A GB0427131D0 (en) 2004-12-10 2004-12-10 Novel combination
PCT/EP2005/013409 WO2006061253A2 (en) 2004-12-10 2005-12-08 Combination of tyrosine kinase inhibitor and her-2/neu for cancer therapy

Publications (1)

Publication Number Publication Date
NO20072668L true NO20072668L (no) 2007-09-04

Family

ID=34073534

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20072668A NO20072668L (no) 2004-12-10 2007-05-25 Ny kombinasjon

Country Status (15)

Country Link
US (1) US20100028414A1 (no)
EP (1) EP1824509A2 (no)
JP (1) JP2008523017A (no)
KR (1) KR20070098857A (no)
CN (1) CN101115499A (no)
AU (1) AU2005313439A1 (no)
BR (1) BRPI0518619A2 (no)
CA (1) CA2589981A1 (no)
GB (1) GB0427131D0 (no)
IL (1) IL183448A0 (no)
MA (1) MA29133B1 (no)
MX (1) MX2007006927A (no)
NO (1) NO20072668L (no)
RU (1) RU2007120462A (no)
WO (1) WO2006061253A2 (no)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7972602B2 (en) 2006-08-11 2011-07-05 Dendreon Corporation Promiscuous HER-2/Neu CD4 T cell epitopes
WO2008088861A2 (en) * 2007-01-18 2008-07-24 University Of Southern California Gene polymorphisms predictive for dual tki therapy
US8623592B2 (en) * 2008-08-15 2014-01-07 Merrimack Pharmaceuticals, Inc. Methods and systems for predicting response of cells to a therapeutic agent
EA201100268A1 (ru) * 2008-08-28 2011-10-31 Глаксосмитклайн Байолоджикалс С.А. Вакцина
WO2012018260A1 (en) * 2010-08-05 2012-02-09 Universiteit Utrecht Holding B.V. Epidermal growth factor receptor targeted immune therapy
JP6748100B2 (ja) * 2015-03-19 2020-08-26 エアロバイロメント, インコーポレイテッドAerovironment, Inc. 機械的衝撃耐性プリント回路基板（ｐｃｂ）への取り付けシステム
RU2603943C1 (ru) * 2016-02-01 2016-12-10 Индивидуальный предприниматель Михайлов Олег Ростиславович КРИСТАЛЛИЧЕСКАЯ γ-МОДИФИКАЦИЯ N-{3-ХЛОР-4-[(3-ФТОРБЕНЗИЛ)ОКСИ] ФЕНИЛ}-6-[5-({[2-(МЕТАНСУЛЬФОНИЛ)ЭТИЛ]АМИНО}МЕТИЛ)-2-ФУРИЛ]-4-ХИНАЗОЛИНАМИНА БИС (4-МЕТИЛБЕНЗОЛСУЛЬФОНАТА) МОНОГИДРАТА, СПОСОБ ЕЁ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ЕЁ ОСНОВЕ
US20210121518A1 (en) * 2018-02-15 2021-04-29 Board of Supervisors for the University of Louisiana System Her2-targeted peptidomimetics grafted onto multicyclic peptide scaffolds and methods and uses

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4436727A (en) * 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4866034A (en) * 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4877611A (en) * 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5759551A (en) * 1993-04-27 1998-06-02 United Biomedical, Inc. Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines
US5856462A (en) * 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
GB9717953D0 (en) * 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
RS49779B (sr) * 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
MXPA01007721A (es) * 1999-01-29 2003-07-14 Corixa Corp Proteinas de fusion her-2/neu.
CN1305872C (zh) * 2000-06-30 2007-03-21 葛兰素集团有限公司 喹唑啉类化合物的制备方法
AU2002236765A1 (en) * 2001-01-16 2002-07-30 Glaxo Group Limited Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
WO2005011607A2 (en) * 2003-08-01 2005-02-10 Smithkline Beecham Corporation Treatment of cancers expressing p95 erbb2
SG135193A1 (en) * 2003-08-18 2007-09-28 Pfizer Prod Inc Dosing schedule for erbb2 anticancer agents

Also Published As

Publication number Publication date
US20100028414A1 (en) 2010-02-04
EP1824509A2 (en) 2007-08-29
RU2007120462A (ru) 2009-01-20
JP2008523017A (ja) 2008-07-03
KR20070098857A (ko) 2007-10-05
AU2005313439A1 (en) 2006-06-15
GB0427131D0 (en) 2005-01-12
CN101115499A (zh) 2008-01-30
MX2007006927A (es) 2007-06-26
MA29133B1 (fr) 2008-01-02
BRPI0518619A2 (pt) 2008-11-25
IL183448A0 (en) 2007-09-20
WO2006061253A3 (en) 2006-11-16
WO2006061253A2 (en) 2006-06-15
CA2589981A1 (en) 2006-06-15

Similar Documents

Publication Publication Date Title
NO20072668L (no) Ny kombinasjon
EA200700096A1 (ru) Производные 2-карбамид-4-фенилтиазола, способ их получения и их применение в терапии
CY1111797T1 (el) Τοπικη φαρμακοτεχνικη μορφη ιβερμεκτινης για την θεραπεια δερματολογικων καταστασεων
EA200501849A1 (ru) Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ
DK1519724T3 (da) Fredericamycin-derivater som lægemidler til behandling af tumorer
NO20170633A1 (no) Forbindelser av indolamin-2,3-dioksygenase for anvendelse i behandling av kreft i kombinasjon med et anti-PD-1 antistoff .
BRPI0507198A (pt) derivados de bisariluréia
BRPI0510177B8 (pt) composto, composição farmacêutica e uso do mesmo
DK1565471T3 (da) Quionolinylpyrazoler
EA200870193A1 (ru) Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
CY1106386T1 (el) Υποκατεστημενα παραγωγα 3-πυρρολιδιν-ινδολης
DE602004027936D1 (de) Tocopherolmodifizierte therapeutische arzneimittelverbindung
NO20050204L (no) Kombinasjoner av legemidler for behandling av neoplasmer
BRPI0318811B8 (pt) derivados de ciclohexanol espirocíclicos
EA200700851A1 (ru) Получение и применение бифенил-4-илкарбониламинокислотных производных для лечения ожирения
BR0315580A (pt) Derivados de metileno uréia
DK1885187T3 (da) Fremgangsmåde til behandling af lægemiddelresistent cancer
NO20045354L (no) Fremgangsmater for behandling av angiogenese, turmorvekst og metastaser
ECSP045353A (es) Derivados de benzoxazinona, su preparación y aplicación como medicamentos
DK1594885T3 (da) Lægemiddel til vækstinhibering af tumorer
CY1115629T1 (el) Χρηση ενωσεων πεπτιδιου τρο και φαρμακευτικων συνθεσεων στην θεραπεια της αναιμιας
EA200501821A1 (ru) Фармацевтическая комбинация, содержащая модафинил и другой лекарственный препарат
MXPA05010020A (es) Derivados de oxamida.
AR048672A1 (es) Tabletas de desintegracion que comprenden licarbazepina
EA200501310A1 (ru) Производные бензолсульфонамидов, способ их получения и их применение для лечения боли

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application